Laboratoire d’Hématologie, Institut de Biologie, 44000 Nantes, et INSERM U601
Even though no cure is observed in multiple myeloma (MM), some patients may enjoy long survival. Many prognostic factors (both clinical and biological) have been described. The goal of this work is to critically review these parameters. Actually, the combination of several factors enables to optimize the predictive power of survival. So far, the most powerful parameters are the serum levels of β2-microglobulin and chromosomal abnormalities. The systematic use of genetic and genomic techniques should allow the description of a prognostic classification in MM, as previously described in acute leukemias.